Drugs and patents in ATC class S01BC - Antiinflammatory agents, non-steroids

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
OXYPHENBUTAZONE	oxyphenbutazone
TANDEARIL	oxyphenbutazone
ZORVOLEX	diclofenac
FLECTOR	diclofenac epolamine
LICART	diclofenac epolamine
>Tradename	>Generic Name

Last updated: June 7, 2026

Executive summary

ATC S01BC (antiinflammatory agents, nonsteroids) is dominated by ophthalmic NSAID actives and their line extensions, including diclofenac (commonly as sodium diclofenac ophthalmic solution), ketorolac (as tromethamine ophthalmic preparations), and related NSAID ophthalmics. Patent activity in this class clusters around (1) first-in-class compositions and early drug-substance processes, (2) ophthalmic formulation and stabilization systems, (3) dosing regimens tied to ocular indications, and (4) device and manufacturing/sterile fill strategies that enable patent-anchored “authorized generics” or switches. Market dynamics are shaped by post-surgery volume (cataract and refractive workflows), branded-to-generic substitution waves, and FDA Orange Book–driven regulatory entry strategies (especially Paragraph IV for immediate-release and lower-barrier generics).

For this ATC class, the key business issue is not “one patent estate,” but multiple overlapping estates across actives, strengths, and indications. Once the composition-of-matter and key formulation patents expire, competitive pressure typically accelerates through generics and authorized generics, with remaining barriers shifting to method-of-use and device/manufacturing patents.

What specific drugs sit in ATC S01BC and how do they compete commercially?

ATC S01BC is the NSAID antiinflammatory ophthalmic segment. The competitive set is built around topical ocular NSAIDs used for:

post-operative ocular inflammation control (especially after cataract surgery)
pain/inflammation reduction in defined ophthalmic settings (indication depends on product labeling and jurisdiction)
adjunct anti-inflammatory control in anterior segment procedures

Which active ingredients define the S01BC competitive field?

In practice, the S01BC market is driven by:

diclofenac sodium ophthalmic preparations
ketorolac tromethamine ophthalmic preparations
Other NSAID ophthalmics may appear in nearby taxonomies depending on classification mapping, but these two actives anchor the US-facing and EU-facing pharmacy channels most consistently for S01BC-like antiinflammatory NSAID use.

What are the main demand drivers?

Cataract surgery throughput and perioperative protocols
Growth in outpatient ophthalmology and standardized post-op antiinflammatory pathways
Switching dynamics between branded and generic products at the pharmacy counter, followed by channel lock-in through contracts

What does switching look like after generic entry?

Branded price compression once an ANDA-approved generic reaches the market
“Staged substitution,” where the first generic entry captures routine utilization, then additional SKUs/strengths compete via contracting and payer formularies
Indication-anchored retention, when method-of-use patents or label-specific formulations delay substitution

How do patents typically break down across ophthalmic NSAIDs in S01BC?

Patent estates in topical ocular NSAIDs tend to be layered. The layers matter because each layer maps to a different generic design-around strategy.

Composition-of-matter and early priority families

Drug-substance composition, salts, and key intermediates
Early synthesis routes that can support process patents
Crystallinity/polymorph or salt form claims where applicable

Generic risk: High after composition-of-matter and essential process patents expire. Most ANDA entrants can use the same API and rely on bioequivalence plus formulation optimization that avoids later formulation claims.

Formulation and stabilization patents

Ophthalmic NSAID formulations often receive later patents for:

buffers and pH targets that reduce irritation and improve tolerability
viscosity agents and tonicity adjustments
antioxidant systems to limit oxidative degradation
preservatives and preservative-free packaging strategies
water activity, antimicrobial effectiveness, and sterility assurance controls

Generic risk: Medium to high. ANDA applicants can often omit non-essential features, but formulation patents can block direct copies of stabilization systems if claims are narrow enough.

Method-of-use and dosing regimen patents

Claims frequently target:

dosing schedules post-surgery (timing around procedure)
specific indication windows
combined regimens with other ophthalmics (depending on the claim scope)

Generic risk: Medium. Even with expired composition patents, method-of-use patents can deter entry if the ANDA certification challenges those patents and potential design-around fails to match the patented regimen.

Device and packaging/manufacturing patents

For ophthalmic topicals:

sterile fill process patents
container closure system compatibility
particulate control and filtration parameters
preservative-free unit-dose packaging claims

Generic risk: Lower if claims are narrow to manufacturing steps, but it can still matter when claims are asserted against the ANDA product’s production method.

What patents protect topical diclofenac and how strong is the estate?

Diclofenac sodium ophthalmic formulations are a core S01BC product class component. The patent landscape typically follows:

early composition-of-matter and salt/intermediate families
later formulation and stability improvement families
indication or regimen patents tied to perioperative use

Key claim zones for diclofenac ophthalmics

API composition and synthesis

Strongest barrier period is the first priority composition family and key process patents.

Ophthalmic formulation

Stabilizing buffers, tonicity systems, and preservative selections can create additional claim layers.

Dosing regimen

Post-operative dosing claims can delay entry for label-specific regimens.

How does strength translate to practical entry barriers?

When composition patents expire but formulation and method-of-use patents remain:

Paragraph IV filings tend to concentrate on patents that can be carved out by formulation changes
Court outcomes often turn on whether generic products literally infringe a formulation claim or do not infringe method-of-use claims based on label timing and instructions

Commercial impact pattern: Entry accelerates once generic product can be launched without triggering injunction risk on formulation or regimen claims.

What patents protect topical ketorolac and how strong is the estate?

Ketorolac tromethamine ophthalmic products also anchor the S01BC market. Patent stacking is similar:

early composition-of-matter and related synthetic intermediates
formulation system improvements
dosing method-of-use protections tied to ocular anti-inflammatory regimens

Claim zones relevant to ketorolac entry risk

Sterility and particulate control during ophthalmic sterile fill can be a claim target.
Stabilization to minimize degradation under ophthalmic storage conditions can be protected.
Dosing schedules can be claimed as method-of-treatment in specific post-procedure windows.

What shifts after core composition expiration?

After the earliest API families expire:

generic competition increases, typically via ANDA approvals and early retailer uptake
lingering formulation/method patents can produce slower uptake in specific SKUs (preservative-free vs preserved, single-dose vs multidose)

When does exclusivity end for S01BC drugs and what timelines matter?

Exclusivity for ophthalmic NSAIDs is mostly a function of:

patent expiration for composition-of-matter and key formulation/process claims
regulatory exclusivity (where applicable) tied to new drug approval dates and pediatric exclusivity, though for established actives the practical driver is usually patent expiration

Business-relevant timing checkpoints

Patent expiry window: determines earliest allowable noninfringing launch date.
Orange Book listing release timing: affects when Paragraph IV can be filed and when litigation risk peaks.
36-month stay: can delay generic launch after a Paragraph IV certification triggers a litigation filing.

What is the Orange Book status of S01BC ophthalmic NSAIDs?

Orange Book status determines what patents are listed for FDA-approved products and, in the US, drives Paragraph IV and litigation strategy. The key operational point is that for S01BC actives:

multiple patents are often listed, spanning drug substance, drug product, and method-of-use
each ANDA typically targets a subset of those listed patents via Paragraph IV certifications

What to look for in Orange Book listings (strategy view)

how many patents are listed per NDA for each strength and dosage form
categories (drug substance vs drug product vs method-of-use)
which patents are still active when generics attempt entry
whether pediatric exclusivity or other regulatory exclusivities extend launch beyond patent expiry

How many patents cover S01BC products and which assignees dominate?

The S01BC patent landscape generally shows:

originator assignees holding early drug-substance and key formulation patents
secondary assignees and smaller branded holders owning late-stage formulation improvements
generic companies acquiring rights via licensing or entering with ANDAs, then litigating listed patents

Practical mapping for market intelligence

Identify top assignees by active patent counts on the Orange Book products for each active
Track assignee transitions through assignment filings
Monitor continuation-family filings that extend formulation protections

What Paragraph IV challenges drive generic entry risk in S01BC?

Paragraph IV filings are the dominant mechanism for challenge-led entry for small-molecule ophthalmics, because:

ANDA entrants can certify noninfringement or invalidity for listed patents
Paragraph IV litigation can lead to settlements and negotiated entry dates

What patents are most commonly targeted?

formulation patents that can be designed around through different stabilization systems
method-of-use patents where label changes can avoid infringement
secondary process patents, depending on manufacturing verification evidence and claim scope

What patterns show up in settlements?

Settlements for ophthalmic NSAIDs commonly:

set “at-risk” launch dates aligned with non-infringement or last-expiring patent
grant nonexclusive licenses to permit entry under specific constraints
include covenants not to sue for certain patents for defined periods

What patent litigation affects S01BC ophthalmic NSAIDs?

Ophthalmic NSAID litigation typically centers on:

alleged infringement of formulation or dosing regimen claims
validity arguments grounded in obviousness and lack of novelty relative to earlier art
claim construction disputes that determine whether a generic’s formulation or label practices fall within claim scope

What outcomes matter commercially?

Court rulings that narrow claim scope can unlock generic entry even before the last patent expires.
Settlement agreements can accelerate or delay entry relative to pure patent expiry.

How does biosimilar risk apply to S01BC?

Biosimilar risk is not a primary framework for S01BC because the segment is nonsteroidal antiinflammatory ophthalmics, generally small molecules rather than biologics. The competitive bottleneck is instead ANDA-style generic entry and, where relevant, new topical delivery formats that introduce separate patent estates.

How do S01BC products compare: diclofenac vs ketorolac for market access?

From a patent and entry standpoint, the comparison is less about clinical performance and more about:

how many patents remain listed at the time of attempted generic entry
whether remaining patents are design-aroundable (formulation) or more label-bound (method-of-use)
whether the originator has multiple strengths/dosage forms protected by parallel estates

Patent-driven competitive differentiation

If one active has heavier formulation and method-of-use patent stacking, it delays generic penetration and preserves branded share longer.
If another active has fewer late patents, generic entry is faster and price compression begins sooner.

Where are the formulation and manufacturing IP barriers most likely?

For topical ocular NSAIDs, the barriers that most often survive early composition expiry are:

stabilization chemistry (pH, antioxidants, buffers)
preservative system claims, including preservative-free approaches
sterile fill and container closure compatibility
particulate and filtration method claims used to meet ophthalmic quality specs

What generic entrants do to reduce infringement risk

select alternative buffers/pH targets that remain within functional ranges but avoid literal claim coverage
change preservatives or preservative concentration if claims are specific
adjust viscosity system and tonicity agents to avoid formulation claim overlap
align labeling and dosing instructions to avoid method-of-use triggers

What generic entry risks exist for S01BC if core patents expire?

When composition-of-matter expires, remaining risk is mostly:

formulation claim coverage that blocks “copy-exact” products
method-of-use coverage that restricts label entry
packaging/manufacturing claims that prevent use of a specific sterile fill process or container system

Market outcomes if patents do not block entry

rapid erosion of branded revenue
consolidation of channel supply to lowest-cost generics and authorized generics
slower brand recovery unless brand introduces new differentiated SKUs (new dosing schedule, preservative-free, or new strength) with fresh patent coverage

What geographic coverage matters for S01BC patent enforcement?

Market dynamics and enforceability depend on whether:

originators pursue parallel patents in the US and major EU jurisdictions
generic challenges proceed in the jurisdiction with the strongest injunction leverage
formulation patents have corresponding equivalents abroad

Enforcement posture that impacts market entry

US: Orange Book listing drives Paragraph IV and settlement leverage.
EU: national marketing authorization and patent enforcement can create parallel blockers depending on validity and enforcement venues.

Key Takeaways

S01BC’s competitive structure is built on topical ocular NSAIDs, primarily diclofenac and ketorolac, with patent estates that cluster around formulation stabilization, dosing regimens, and sterile manufacturing.
Generic entry is driven by ANDA Paragraph IV strategy against Orange Book-listed patents; the highest risk typically shifts from composition-of-matter to formulation and method-of-use layers as core patents expire.
Market share erosion accelerates after composition expiry unless formulation or method-of-use patents delay launch or force design-around or settlements.
Biosimilar risk is not the primary concern in S01BC; the operative threat is generic small-molecule entry and label/formulation design-around.

FAQs

1) What is the Orange Book listing structure for ophthalmic NSAID NDAs in S01BC?
Expect multiple listed patents per product, spanning drug substance, drug product, and method-of-use, with entry strategy built around which subset is challenged.

2) Which patents are easiest to design around for generic ophthalmic diclofenac or ketorolac?
Formulation patents that target specific stabilization components can be vulnerable to alternative excipient and pH/buffer system selections, depending on claim scope.

3) Does changing the dosing label avoid method-of-use patent risk in S01BC?
Method-of-use claims can be avoided when label instructions and real-world use do not fall within claim timing/schedule, but infringement analysis depends on claim construction.

4) What settlement terms usually appear in ophthalmic NSAID Paragraph IV cases?
Courts and settlements commonly coordinate launch dates and carve out patent coverage with covenants not to sue for defined periods and scopes.

5) How do preservative-free or unit-dose product formats change the patent landscape in S01BC?
They can trigger separate formulation and packaging/process patent estates, extending exclusivity even after composition-of-matter for the base API expires.

References

No sources were provided in the prompt, and no external patent/Orange Book datasets or FDA product records were supplied for ATC S01BC specifics.